127
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Next-generation sequencing reveals a novel pathogenic variant in the ATM gene

, , &
Pages 558-562 | Received 26 Jul 2019, Accepted 07 Sep 2020, Published online: 24 Jan 2021
 

Abstract

Introduction

Ataxia telangiectasia (A-T) is a rare autosomal recessive, multisystemic disease. Patients with the A-T syndrome present a broad spectrum of disease phenotypes. The ATM (ataxia telangiectasia mutated) gene, the only causative gene for A-T.

Method

A patient of Persian origin presenting with typical A-T was referred to our genetics centre for specialized genetic counselling and testing. Targeted next-generation sequencing (NGS) was applied. Sanger sequencing was used to confirm the candidate variant. Modelling was performed using the SWISS-MODEL server.

Results

A homozygous stop-gain variant c.829G > T (p.E277*) was found in the ATM gene. This variant was confirmed by Sanger sequencing and modelling of native structure, and truncated structure was performed.

Conclusion

To date, very few pathogenic variants of the ATM gene have been reported from the Iranian population. The finding has implications in molecular diagnostic for A-T in Iran.

Disclosure statement

No potential conflict of interest was reported by the authors. Patients have filled out Informed consent.

Additional information

Funding

The project has been funded by Isfahan University of Medical Sciences and Ahvaz Noor Medical Genetics Lab.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.